Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
“Breakthrough Therapy”
10 result(s)
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for... More
White Paper
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
An overview of recently approved therapies, anticipated approvals in the year to come, and strategies to help manage the pipeline More
Feature
Drug Pipeline
Peanut allergy is the most common of childhood food allergies — and getting more common. Research presented at the annual meeting of the American College of Allergy, Asthma and... More
Feature
Cost Management
Epidiolex, the latest cannabis-based drug to be approved by the FDA to treat certain seizure disorders, is a highly potent form of cannabidiol. Given the narrow indication and... More
Feature
Specialty
Treatment options for hemophilia continue to expand, which is good news for patients. Recently approved therapy options offer better outcomes but need careful management. More
Briefing
Drug Pipeline
When the FDA approves a “supplemental indication” for a drug already on the market — permitting it to be used for new conditions or stages of a disease, or additional patient... More
Briefing
Cost Management
High Drug Prices: Who is Responsible?
With prescription drug prices very much in the news, the question often asked is: Who is responsible for high drug prices? Pharmaceutical manufacturers — and no one else — set... More
Commentary
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature